Be the first to like this
Within the frame of the Swiss Animal Health Strategy 2010+ (www.bvet.admin.ch), the Swiss Federal Veterinary Office initiated a project in order to evaluate a vaccination-to-live strategy against Foot …
Within the frame of the Swiss Animal Health Strategy 2010+ (www.bvet.admin.ch), the Swiss Federal Veterinary Office initiated a project in order to evaluate a vaccination-to-live strategy against Foot and Mouth Disease (FMD). Within the scope of this project, the benefit of emergency vaccination within 3 km (V3) and 10 km (V10) around an infected premises (IP) was evaluated and the technical feasibility of such an emergency vaccination was analyzed regarding the corresponding EU FMD directive (COUNCIL DIRECTIVE 2003/85/EC).
We used the Davis Animal Disease Simulation (DADS) model (Carpenter et al., 2011; Durr et al., 2012) in order to compare the conventional disease control strategy with and without an additional emergency vaccination strategy (V3 and V10, respectively). In a second step, we analyzed the implementation of a vaccination-to-live strategy with regard to its feasibility and economical consequences.
It was shown that emergency vaccination in a low-livestock density country like Switzerland would be only beneficial in a situation where the epidemic is already widely distributed (V10 strategy). On the other hand, our feasibility study with respect to the vaccination-to-live strategy revealed that the animal movement restrictions within the vaccination zone would lead to a significant increase in welfare culling especially in the pig production sector due to the long duration of the restrictions.
The expected increase in welfare culling due to the long duration of animal movement restrictions within the vaccination zone actually impedes the implementation of a vaccination-to-live strategy for ethical and economic reasons. Therefore, the implementation of animal movement restrictions during the different phases of a vaccination-to-live process has to be re-examined and adjusted accordingly.
(c) D. C. Hadorn / EuFMD (email@example.com)